LINC02273: A Potential Drug Target and Biomarker (G100996286)

Target Name: LINC02273

NCBI ID: G100996286

LINC02273

Other Name(s): Long intergenic non-protein coding RNA 2273, transcript variant 1 | long intergenic non-protein coding RNA 2273

LINC02273: A Potential Drug Target and Biomarker

LINC02273 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and is involved in the development and progression of various diseases, including cancer. LINC02273 has been shown to have a positive impact on cancer cell survival and has been identified as a potential drug target in multiple studies.

The cell cycle is a critical process that regulates the growth and development of cells. The cell cycle includes the G1, S, G2, and M phases, and each phase is responsible for specific cellular tasks. LINC02273 is a key regulator of the cell cycle and is involved in the regulation of G1 phase.

G1 phase is the first phase of the cell cycle and is responsible for the preparation of the cell for cell division. During G1 phase, LINC02273 plays a critical role in the regulation of the cell cycle and the maintenance of the cell's normal size and shape.

LINC02273 has been shown to have a positive impact on cancer cell survival. Studies have shown that LINC02273 can inhibit the inhibition of the G1 phase, leading to an increase in the length of the G1 phase and a delay in the start of the S phase. This has been shown to lead to an increase in the number of cells that are able to divide and a higher overall survival rate.

In addition to its impact on cancer cell survival, LINC02273 has also been shown to have a positive impact on normal cell survival. Studies have shown that LINC02273 can protect normal cells from the inhibition of the G1 phase, leading to an increase in the length of the G1 phase and a delay in the start of the S phase. This has been shown to lead to a higher overall survival rate in normal cells.

LINC02273 has also been shown to have a positive impact on the progression of cancer. Studies have shown that LINC02273 can inhibit the inhibition of the G1 phase, leading to an increase in the length of the G1 phase and a delay in the start of the S phase. This has been shown to lead to an increase in the number of cells that are able to divide and a higher overall survival rate in cancer cells.

In conclusion, LINC02273 is a non-coding RNA molecule that has been shown to have a positive impact on cancer cell survival and the progression of cancer. It is a potential drug target and biomarker and may be a valuable tool in the development of new cancer therapies. Further research is needed to fully understand the impact of LINC02273 on cancer cell survival and the progression of cancer.

Protein Name: Long Intergenic Non-protein Coding RNA 2273

The "LINC02273 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02273 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets